Cationic Adjuvant Composition for Dual Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adjuvants for vaccines, such as aluminium-based adjuvants and squalene emulsions, are inadequate in inducing robust cell-mediated immune (CMI) responses, which are essential for protecting against pathogens like tuberculosis, HIV, and malaria.
Innovation Solution
A novel adjuvant composition comprising dimethyldioctadecyl ammonium salt (DDA), monomycolyl glycerol (MMG), and the CpG ODN 2006 oligodeoxynucleotide, which synergistically enhances both antibody and T cell responses without inducing systemic side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If aluminium-based adjuvants or squalene emulsions are used, then humoral immune response is induced, but cell-mediated immune response is insufficient
Solution Approach 1:
The patent combines DDA/MMG liposomal adjuvant system with CpG ODN 2006 to create a synergistic formulation that simultaneously induces both humoral (IgG2c) and cell-mediated (Th1/17) immune responses. This merging of adjuvant components resolves the contradiction by providing dual immune activation without compromising protection against pathogens.
Solution Approach 2:
The invention uses a composite adjuvant system comprising DDA, MMG, and CpG ODN 2006 in a liposomal formulation. This composite material approach enables the adjuvant to engage multiple immune pathways simultaneously, achieving robust cell-mediated response while maintaining humoral response for comprehensive pathogen protection.
2Quantity of substance
If high doses of CpG ODN are used to increase immune response, then antibody and T cell responses are enhanced, but systemic side effects occur
Solution Approach 1:
The DDA/MMG liposomal formulation acts as an intermediary carrier that delivers CpG ODN 2006 to specific immune cells in a controlled manner. This intermediary system enables effective immune stimulation at lower CpG doses by improving delivery efficiency and reducing non-specific distribution, thereby minimizing systemic side effects.
Solution Approach 2:
The patent optimizes the formulation parameters of the liposomal system (DDA/MMG ratio, particle size, surface charge) to enhance CpG ODN 2006 uptake by immune cells. By changing these parameters, the system achieves maximum immune response at reduced CpG doses, avoiding dose-related systemic adverse effects.
3Quantity of substance
If existing adjuvants are used to stimulate humoral response, then antibody production is increased, but cell-mediated immunity is not adequately stimulated
Solution Approach 1:
The DDA/MMG/CpG ODN 2006 adjuvant system is designed with multi-functionality to simultaneously stimulate both humoral and cell-mediated immune responses. The formulation universally activates multiple immune pathways including TLR9 signaling for CpG recognition, leading to coordinated production of IgG2c antibodies and Th1/17 cells for comprehensive immune protection.
Data Source
AI summary
The present invention relates to an adjuvant composition comprising dimethyldioctadecyl ammonium salt (DDA), monomycoloyl glycerol (MMG), and the CpG ODN 2006 oligodeoxynucleotide having SEQ ID NO:1 or a sequence having 90% identity to SEQ ID NO:1. Another aspect of the present invention is a vaccine comprising said adjuvant composition and at least one antigen, and the use of said vaccine in prevention or treatment of an infectious disease.